VOR:NASDAQ, Vor Biopharma Inc.
VOR stock overview
Vor Biopharma Inc. (VOR:NASDAQ) closed at $18.26 on October 23, 2026,
down 3.59% on the day.
The stock trades 36.3% below its 52-week high of $28.66
and 180.9% above its 52-week low of $6.50.
Over the past year, it lost 32.8%.
Vor Biopharma Inc. is part of the Health Care sector.
Key figures
- Price
- $18.26
- Day change
- -3.59%
- Volume
- 720,921
- Average volume
- 957,551
- Market cap
- 1B+
- 52-week range
- $6.50 – $28.66
- 50-day average
- $21.19
- 200-day average
- $17.16
Price action over the past year
In 252 trading sessions since October 23, 2025, VOR closed higher on 115 days (46%).
Its best day was December 9, 2025 (+28.23%) and its worst was November 11, 2025 (-47.66%).
The stock moved 10% or more in a single session 25 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
VOR news
-
Oct 22, 2026:
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
-
Oct 8, 2026:
Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus
-
Oct 5, 2026:
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Oct 4, 2026:
Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)
-
Sep 29, 2026:
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
-
Sep 29, 2026:
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
-
Sep 16, 2026:
Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
-
Sep 8, 2026:
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
About Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Similar stocks
Find more stocks like VOR with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.